Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02747186 · ClinicalTrials.gov registry record · NA

Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT02747186 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02747186, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

Anecdotal data suggest that the buffered form of the local anesthetic is more potent at equal dosages, and a lower dosage of the buffered drug might be used with an effect equal to higher dosage not buffered. Clinical data are needed to confirm these anecdotal data. No published data exist comparing buffered local anesthetics at lower drug concentrations to current dosages commonly used in dental and oral surgical procedures

Interventions

  • DRUG Lidocaine

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-05
Est. Completion 2017-12-31
Phase NA

What the Registry Record Tells You About NCT02747186

The ClinicalTrials.gov registry entry for NCT02747186 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lidocaine is the first listed.

NCT02747186 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02747186 about?

NCT02747186 is a clinical study titled "Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine". Anecdotal data suggest that the buffered form of the local anesthetic is more potent at equal dosages, and a lower dosage of the buffered drug might be used with an effect equal to higher dosage not buffered. Clinical data are needed to confirm these anecdotal data. No published data exist comparing...

What is the current status of trial NCT02747186?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2016-05. Estimated completion is 2017-12-31.

What interventions are being tested in trial NCT02747186?

The interventions under investigation include: Lidocaine (DRUG).

Who is sponsoring clinical trial NCT02747186?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.